PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for April 7, 2008 Subscribe to this News Feed    
 

TomoTherapy Co-Founder to Speak at North Carolina IMRT/IGRT Symposium

MADISON, Wis. (Business Wire EON/PRWEB ) April 7, 2008 -- TomoTherapy Incorporated (NASDAQ: TOMO) announced today that company co-founder Thomas Rock Mackie, Ph.D., will speak at an upcoming symposium on intensity-modulated and image-guided radiation therapy (IMRT/IGRT). The symposium, co-sponsored by Duke University and East Carolina University, will be held on April 19, 2008 in Greenville, N.C. Dr. Mackie will discuss the clinical advantages of TomoTherapys unique, highly-modulated mode of radiation delivery.

I am honored to accept this invitation to speak, said Dr. Mackie. I look forward to the opportunity to discuss with my colleagues how helical TomoTherapy® is able to achieve consistently high-quality dose distributions across a wide range of cases. Weve effectively eliminated the need for clinical reliance upon complex techniques such as non-axial or non-coplanar arcs.

News Image The TomoTherapy® Hi·Art® treatment system is a novel radiation therapy platform that uses a patented binary multi-leaf collimator (MLC) to modulate the radiation beam as it rotates around the patient. The system includes integrated 3D CT-based image guidance and adaptive radiation therapy, leveraging the design advantages of a CT platform and the tight integration afforded by a centralized planning, imaging and treatment database.

Dr. Mackie co-founded TomoTherapy with Paul Reckwerdt in 1997, and currently serves as the companys chairman of the board. Dr. Mackie is also a professor in the departments of Medical Physics and Human Oncology at the University of Wisconsin.

This will be the second annual North Carolina IMRT/IGRT Symposium. This years theme is Integrating New Technology in Radiation Oncology. In speaking at this event, Dr. Mackie will join professors and clinicians from East Carolina University School of Medicine, Duke University Medical Center, University of North Carolina at Chapel Hill School of Medicine, Wake Forest University, and Baptist Medical Center.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The companys stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

See the original story at: http://eon.businesswire.com/releases/tomotherapy/university/prweb836834.htm

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1DcmFzLVNxdWEtU3VtbS1TdW1tLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION

TomoTherapy Incorporated
Investor Contact:
Stephen C. Hathaway
Chief Financial Officer
608.824.2800
shathaway@tomotherapy.com
or
Media Contact:
Patty Kitowski
Marketing Communications Manager
608.824.2820
pkitowski@tomotherapy.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move